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Identification of α-glucosidase inhibitorsfrom Clinacanthus nutans leaf extract using 
liquid chromatography-mass spectrometry-based metabolomics and protein-ligand 
interaction with molecular docking 
ABSTRACT 
The present study used in vitro and in silico techniques, as well as the metabolomics 
approach to characterise α-glucosidase inhibitors from different fractions of Clinacanthus 
nutans. C. nutans is a medicinal plant belonging to the Acanthaceae family, and is 
traditionally used to treat diabetes in Malaysia. n-Hexane, n-hexane: ethyl acetate (1:1, v/v), 
ethyl acetate, ethyl acetate: methanol (1:1, v/v), and methanol fractions were obtained via 
partitioning of the 80% methanolic crude extract. The in vitro α-glucosidase inhibitory 
activity was analyzed using all the fractions collected, followed by profiling of the 
metabolites using liquid chromatography combined with mass spectrometry. The partial least 
square (PLS) statistical model was developed using the SIMCA P+14.0 software and the 
following four inhibitors were obtained: (1) 4,6,8-Megastigmatrien-3-one; (2) N-Isobutyl-2-
nonen-6,8-diynamide; (3) 1′,2′-bis(acetyloxy)-3′,4′-didehydro-2′-hydro-β, ψ-carotene; and (4) 
22-acetate-3-hydroxy-21-(6-methyl-2,4-octadienoate)-olean-12-en-28-oic acid. The in silico 
study performed via molecular docking with the crystal structure of yeast isomaltase (PDB 
code: 3A4A) involved a hydrogen bond and some hydrophobic interactions between the 
inhibitors and protein. The residues that interacted include ASN259, HID295, LYS156, 
ARG335, and GLY209 with a hydrogen bond, while TRP15, TYR158, VAL232, HIE280, 
ALA292, PRO312, LEU313, VAL313, PHE314, ARG315, TYR316, VAL319, and TRP343 
with other forms of bonding. 
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